303 related articles for article (PubMed ID: 18577289)
1. Levodopa improves time-based prospective memory in Parkinson's disease.
Costa A; Peppe A; Brusa L; Caltagirone C; Gatto I; Carlesimo GA
J Int Neuropsychol Soc; 2008 Jul; 14(4):601-10. PubMed ID: 18577289
[TBL] [Abstract][Full Text] [Related]
2. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
3. Prospective memory impairment in individuals with Parkinson's disease.
Costa A; Peppe A; Caltagirone C; Carlesimo GA
Neuropsychology; 2008 May; 22(3):283-92. PubMed ID: 18444706
[TBL] [Abstract][Full Text] [Related]
4. Basal ganglia, dopamine and temporal processing: performance on three timing tasks on and off medication in Parkinson's disease.
Jones CR; Malone TJ; Dirnberger G; Edwards M; Jahanshahi M
Brain Cogn; 2008 Oct; 68(1):30-41. PubMed ID: 18378374
[TBL] [Abstract][Full Text] [Related]
5. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
[TBL] [Abstract][Full Text] [Related]
6. Patients with Parkinson's disease can successfully remember to execute delayed intentions.
Altgassen M; Zöllig J; Kopp U; Mackinlay R; Kliegel M
J Int Neuropsychol Soc; 2007 Sep; 13(5):888-92. PubMed ID: 17697419
[TBL] [Abstract][Full Text] [Related]
7. Impact of Parkinson's disease and dopaminergic medication on proprioceptive processing.
Mongeon D; Blanchet P; Messier J
Neuroscience; 2009 Jan; 158(2):426-40. PubMed ID: 18996173
[TBL] [Abstract][Full Text] [Related]
8. Semantic activation in Parkinson's disease patients on and off levodopa.
Angwin AJ; Arnott WL; Copland DA; Haire MP; Murdoch BE; Silburn PA; Chenery HJ
Cortex; 2009 Sep; 45(8):950-9. PubMed ID: 19356748
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
[TBL] [Abstract][Full Text] [Related]
10. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
[TBL] [Abstract][Full Text] [Related]
11. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
[TBL] [Abstract][Full Text] [Related]
12. Auditory temporal processing in Parkinson's disease.
Guehl D; Burbaud P; Lorenzi C; Ramos C; Bioulac B; Semal C; Demany L
Neuropsychologia; 2008; 46(9):2326-35. PubMed ID: 18439632
[TBL] [Abstract][Full Text] [Related]
13. A study of salivary secretion in Parkinson's disease.
Bagheri H; Damase-Michel C; Lapeyre-Mestre M; Cismondo S; O'Connell D; Senard JM; Rascol O; Montastruc JL
Clin Neuropharmacol; 1999; 22(4):213-5. PubMed ID: 10442250
[TBL] [Abstract][Full Text] [Related]
14. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O
Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628
[TBL] [Abstract][Full Text] [Related]
15. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.
Brefel-Courbon C; Payoux P; Thalamas C; Ory F; Quelven I; Chollet F; Montastruc JL; Rascol O
Mov Disord; 2005 Dec; 20(12):1557-63. PubMed ID: 16078219
[TBL] [Abstract][Full Text] [Related]
16. Influence of subthalamic deep brain stimulation versus levodopa on motor perseverations in Parkinson's disease.
Herzog J; Möller B; Witt K; Pinsker MO; Deuschl G; Volkmann J
Mov Disord; 2009 Jun; 24(8):1206-10. PubMed ID: 19412937
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic medication boosts action-effect binding in Parkinson's disease.
Moore JW; Schneider SA; Schwingenschuh P; Moretto G; Bhatia KP; Haggard P
Neuropsychologia; 2010 Mar; 48(4):1125-32. PubMed ID: 20018200
[TBL] [Abstract][Full Text] [Related]
18. High-speed memory scanning in Parkinson's disease: adverse effects of levodopa.
Poewe W; Berger W; Benke T; Schelosky L
Ann Neurol; 1991 Jun; 29(6):670-3. PubMed ID: 1892368
[TBL] [Abstract][Full Text] [Related]
19. Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners.
De Letter M; Santens P; Estercam I; Van Maele G; De Bodt M; Boon P; Van Borsel J
Clin Linguist Phon; 2007 Oct; 21(10):783-91. PubMed ID: 17882694
[TBL] [Abstract][Full Text] [Related]
20. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
